Back
About
Developer of a computational pathology module platform aimed at swift diagnostic stratification and cancer detection. The platform utilizes deep learning algorithms based on convolutional and recurrent neural networks, as well as generative models, focusing on breast, prostate, and other major cancer types. This allows clinical researchers and pathologists to understand disease progression with various mutations for more effective treatment.
Headquarters
11 Times Square
37th Floor
New York, NY 10036
United States
Team
William Moye Ph.D - Chief Executive Officer & Board Member,
Peter Hamilton - Chief Operating Officer,
Thomas Fuchs Ph.D - Co-Founder & Chief Scientist
Main competitors
PreciseDx,
Keen Eye,
CureMetrix,
Ibex Medical Analytics,
Inspirata
Investors
Healthcare Venture Partners,
Palkon Capital Management,
Casdin Capital Venture Capital,
Catalio Capital Management,
Johnson & Johnson Innovation
Calls within Tajikistan are free
Investments
Information
The information provided is for informational purposes only and should not be considered as an offer to buy or sell foreign currency, securities and/or other financial instruments. The information presented on this website is not an individual investment recommendation. Financial instruments or transactions mentioned in this section may not be suitable for you, may not correspond to your investment profile, financial situation, investment experience, knowledge, investment objectives, attitude to risk and profitability.
LLC "Exchange Broker" does not guarantee and does not promise future profitability of investments, does not guarantee the reliability of possible investments and the stability of possible income. Investment results in the past do not guarantee income in the future.
LLC "Exchange Broker" is not responsible for possible investor losses in the event of transactions and investments in financial instruments, and also does not guarantee the return, effectiveness and profitability of investments.
LLC "Exchange Broker" hereby informs that it operates in the securities market in accordance with the following professional participant licenses issued by the Ministry of Finance of the Republic of Tajikistan: depository activity No.010/25 dated 25.06.2025; brokerage activity No.007/25 dated 25.06.2025; dealer activity No.008/25 dated 25.06.2025 and securities management activity No.009/25 dated 25.06.2025, and also informs about the risk of a conflict of interest, including as a result of combining various types of professional activity in the securities market.